Log in

RegulatoryBusiness Standard

Caplin Point slides 13% after US FDA flags plant

Negative-99

GreyOak summary

Caplin Point Laboratories shares fell 13.23% over three sessions after the US FDA classified its Gummidipoondi facility as Official Action Indicated (OAI). The FDA cited 10 procedural observations from an unannounced inspection. The company stated there is no material impact on its financials or operations.

What it affects

Source

Read the original at Business Standard

More Caplin Point Laboratories news

All Caplin Point Laboratories news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy